CZ289227B6 - Promotor lidského endoglinového genu a jeho pouľití pro přípravu léčiva - Google Patents
Promotor lidského endoglinového genu a jeho pouľití pro přípravu léčiva Download PDFInfo
- Publication number
- CZ289227B6 CZ289227B6 CZ1998332A CZ33298A CZ289227B6 CZ 289227 B6 CZ289227 B6 CZ 289227B6 CZ 1998332 A CZ1998332 A CZ 1998332A CZ 33298 A CZ33298 A CZ 33298A CZ 289227 B6 CZ289227 B6 CZ 289227B6
- Authority
- CZ
- Czechia
- Prior art keywords
- promoter
- gene
- nucleic acid
- acid construct
- sequence
- Prior art date
Links
- 101000881679 Homo sapiens Endoglin Proteins 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 27
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 230000007815 allergy Effects 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 210000000056 organ Anatomy 0.000 claims abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 4
- 208000007502 anemia Diseases 0.000 claims abstract description 4
- 206010003246 arthritis Diseases 0.000 claims abstract description 4
- 208000015294 blood coagulation disease Diseases 0.000 claims abstract description 4
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- 208000032839 leukemia Diseases 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 210000004027 cell Anatomy 0.000 claims description 39
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 239000012636 effector Substances 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 230000022131 cell cycle Effects 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 208000014912 Central Nervous System Infections Diseases 0.000 claims description 2
- 102000009410 Chemokine receptor Human genes 0.000 claims description 2
- 108050000299 Chemokine receptor Proteins 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 102000003675 cytokine receptors Human genes 0.000 claims description 2
- 108010057085 cytokine receptors Proteins 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 230000003480 fibrinolytic effect Effects 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000013600 plasmid vector Substances 0.000 claims 1
- 210000003705 ribosome Anatomy 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 abstract description 2
- 210000003169 central nervous system Anatomy 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 230000009852 coagulant defect Effects 0.000 abstract description 2
- 239000007943 implant Substances 0.000 abstract 2
- 230000006735 deficit Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 description 31
- 125000003729 nucleotide group Chemical group 0.000 description 31
- 210000002889 endothelial cell Anatomy 0.000 description 26
- 108010036395 Endoglin Proteins 0.000 description 20
- 108010047303 von Willebrand Factor Proteins 0.000 description 14
- 102000012085 Endoglin Human genes 0.000 description 13
- 102100036537 von Willebrand factor Human genes 0.000 description 13
- 229960001134 von willebrand factor Drugs 0.000 description 13
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 108050009340 Endothelin Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108091023043 Alu Element Proteins 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 102000048896 human ENG Human genes 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010090549 Endothelin A Receptor Proteins 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102100040630 Endothelin-1 receptor Human genes 0.000 description 1
- 102000011852 GATA2 Transcription Factor Human genes 0.000 description 1
- 108010075641 GATA2 Transcription Factor Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000019218 Mannose-6-phosphate receptors Human genes 0.000 description 1
- 108050006616 Mannose-6-phosphate receptors Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000881680 Mus musculus Endoglin Proteins 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 101150045640 VWF gene Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000430 cytokine receptor antagonist Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19704301A DE19704301C1 (de) | 1997-02-06 | 1997-02-06 | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ33298A3 CZ33298A3 (cs) | 1998-08-12 |
| CZ289227B6 true CZ289227B6 (cs) | 2001-12-12 |
Family
ID=7819364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ1998332A CZ289227B6 (cs) | 1997-02-06 | 1998-02-04 | Promotor lidského endoglinového genu a jeho pouľití pro přípravu léčiva |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6103527A (enExample) |
| EP (1) | EP0857781A3 (enExample) |
| JP (1) | JPH11178A (enExample) |
| KR (1) | KR19980071084A (enExample) |
| CN (1) | CN1196784C (enExample) |
| AR (1) | AR011110A1 (enExample) |
| AU (1) | AU736724B2 (enExample) |
| BR (1) | BR9800563A (enExample) |
| CA (1) | CA2222981A1 (enExample) |
| CZ (1) | CZ289227B6 (enExample) |
| DE (1) | DE19704301C1 (enExample) |
| HU (1) | HUP9800247A3 (enExample) |
| PL (1) | PL324688A1 (enExample) |
| RU (1) | RU2230115C2 (enExample) |
| TR (1) | TR199800168A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19704301C1 (de) * | 1997-02-06 | 1998-03-26 | Hoechst Ag | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
| HUP9900956A2 (hu) | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
| DE60013586T2 (de) | 1999-04-02 | 2005-02-03 | Hisamitsu Pharmaceutical Co., Inc., Tosu | Genexpressions-basensequenzen zur therapeutischen anwendung und heilmittel zur gentherapie |
| RU2295281C2 (ru) * | 2005-04-20 | 2007-03-20 | Федеральное государственное учреждение Научно-исследовательский институт детских инфекций, г.Санкт-Петербург | Способ оценки тяжести инфекционного поражения цнс у детей |
| RU2297848C2 (ru) * | 2005-05-11 | 2007-04-27 | Александр Веньяминович Иткес | Генно-инженерная конструкция vegf-ибмед (vegf-ibmed) |
| US20090136465A1 (en) | 2007-09-28 | 2009-05-28 | Intrexon Corporation | Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof |
| EP2310507A4 (en) | 2008-07-08 | 2013-03-20 | David Gladstone Inst | METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION |
| EP2951306A4 (en) | 2013-01-30 | 2016-07-27 | Univ Nebraska | COMPOSITIONS AND METHOD FOR TREATING COMPLICATIONS RELATED TO DIABETES |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466596A (en) * | 1992-08-25 | 1995-11-14 | Mount Sinai Hospital Corporation | Tissue specific transcriptional regulatory element |
| GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| DE19704301C1 (de) * | 1997-02-06 | 1998-03-26 | Hoechst Ag | Der Promotor des humanen Endoglingens und seine Verwendung für die Gentherapie |
-
1997
- 1997-02-06 DE DE19704301A patent/DE19704301C1/de not_active Expired - Fee Related
-
1998
- 1998-02-04 AR ARP980100497A patent/AR011110A1/es unknown
- 1998-02-04 CA CA002222981A patent/CA2222981A1/en not_active Abandoned
- 1998-02-04 TR TR1998/00168A patent/TR199800168A2/xx unknown
- 1998-02-04 CZ CZ1998332A patent/CZ289227B6/cs not_active IP Right Cessation
- 1998-02-05 AU AU52931/98A patent/AU736724B2/en not_active Ceased
- 1998-02-05 HU HU9800247A patent/HUP9800247A3/hu not_active Application Discontinuation
- 1998-02-05 EP EP98102014A patent/EP0857781A3/de not_active Withdrawn
- 1998-02-05 RU RU98101849/13A patent/RU2230115C2/ru not_active IP Right Cessation
- 1998-02-05 KR KR1019980003185A patent/KR19980071084A/ko not_active Ceased
- 1998-02-05 CN CNB981063500A patent/CN1196784C/zh not_active Expired - Fee Related
- 1998-02-05 BR BR9800563A patent/BR9800563A/pt not_active IP Right Cessation
- 1998-02-05 JP JP10024524A patent/JPH11178A/ja not_active Withdrawn
- 1998-02-06 PL PL98324688A patent/PL324688A1/xx unknown
- 1998-02-06 US US09/019,689 patent/US6103527A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0857781A2 (de) | 1998-08-12 |
| JPH11178A (ja) | 1999-01-06 |
| TR199800168A2 (xx) | 1998-08-21 |
| KR19980071084A (ko) | 1998-10-26 |
| RU2230115C2 (ru) | 2004-06-10 |
| CN1196784C (zh) | 2005-04-13 |
| CA2222981A1 (en) | 1998-08-06 |
| HUP9800247A3 (en) | 2002-11-28 |
| AU736724B2 (en) | 2001-08-02 |
| CZ33298A3 (cs) | 1998-08-12 |
| US6103527A (en) | 2000-08-15 |
| HU9800247D0 (en) | 1998-03-30 |
| AU5293198A (en) | 1998-08-13 |
| HUP9800247A2 (hu) | 1998-10-28 |
| BR9800563A (pt) | 1999-06-29 |
| AR011110A1 (es) | 2000-08-02 |
| CN1203948A (zh) | 1999-01-06 |
| PL324688A1 (en) | 1998-08-17 |
| EP0857781A3 (de) | 2001-05-16 |
| DE19704301C1 (de) | 1998-03-26 |
| MX9800981A (es) | 1998-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU723325B2 (en) | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors | |
| García-Moruja et al. | Functional characterization of SDF-1 proximal promoter | |
| Danoff et al. | Cloning, genomic organization, and chromosomal localization of the Scya5 gene encoding the murine chemokine RANTES. | |
| JP2005508188A (ja) | 阻害オリゴヌクレオチド及び遺伝子を特異的に抑制するためのそれらの使用 | |
| Ranganathan et al. | Cloning of murine tissue factor and regulation of gene expression by transforming growth factor type beta 1. | |
| JP2010029207A (ja) | ＨＭＧ蛋白質（ｈｉｇｈｍｏｂｉｌｉｔｙｇｒｏｕｐｐｒｏｔｅｉｎ）遺伝子の核酸配列およびそれらの使用 | |
| JP2002512030A (ja) | がん免疫療法に有用な、ｈｓｐ７０から誘導された変異ペプチド化合物 | |
| CZ41897A3 (en) | Structures of nucleic acids for controlled expression of genes, cells containing such structures and their use for preparing medicaments | |
| JP2017500316A (ja) | ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復する方法 | |
| CZ33298A3 (cs) | Promotor lidského endoglinového genu a jeho použití pro přípravu léčiva | |
| JPH10511542A (ja) | 標的化ｔリンパ球 | |
| US20050063948A1 (en) | Methods for targeting interleukin-12 to malignant endothelium | |
| AU5318299A (en) | Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same | |
| WO2000006759A9 (en) | Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same | |
| Eades et al. | The IFN-gamma response of the murine invariant chain gene is mediated by a complex enhancer that includes several MHC class II consensus elements. | |
| EP1108046B1 (en) | Guanylate binding protein (gbp-1) as inhibitor of cell proliferation | |
| US6231850B1 (en) | Canine interleukin 12 | |
| Lee et al. | Molecular analysis of HLA-DR gene expression induced by IFN-7 in malignant melanoma cell lines | |
| JP4579688B2 (ja) | Ｉｌ−１８ｂｐのプロモーター、その製造および使用 | |
| JP2002535372A (ja) | プラスミノーゲンクリングル４領域フラグメントおよび利用法 | |
| HK1017713A (en) | Promoter of the human endoglin gene and its use | |
| MXPA98000981A (en) | Promoter of human endoglin gene and his | |
| Zhang et al. | Extracellular domain of kinase domain region mediated by adeno-associated virus inhibits growth and angiogenesis of bladder cancer in Balb-c mice | |
| KR100419972B1 (ko) | 링커 염기서열로 연결된 인간 ｖｅｇｆ의 돌연변이형동형이합체 유전자, 이를 포함하는 발현벡터, 이의형질전환체 및 단백질 | |
| Ghelardi et al. | Cloning of an unidentified T-cell receptor α chain gene from a vesicular stomatitis virus-specific helper T-cell clone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD00 | Pending as of 2000-06-30 in czech republic | ||
| MM4A | Patent lapsed due to non-payment of fee |
Effective date: 20060204 |